Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Hematology Clinical Drug Pipeline Developments & Deals

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            Product Type filter
              refresh

              Product Type

              Development Status

              Akebia Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference

              Contact the Supplier

              Lead Product(s): AKB-6548

              Therapeutic Area: Hematology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 23, 2020

              Details:

              The posters present studies of Akebia's investigational oral HIF-prolyl hydroxylase inhibitor (HIF-PHI), vadadustat.

              BioCryst Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              BioCryst Begins Proof Of Concept Trial In PNH Patients With Oral Factor D Inhibitor, BCX9930

              Contact the Supplier

              Lead Product(s): BCX9930

              Therapeutic Area: Hematology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 05, 2020

              Details:

              In PNH, goal for BCX9930 is to develop a safe, well-tolerated, oral monotherapy with excellent efficacy, whether or not patients have ever been treated with a C5 inhibitor.

              Domainex

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Domainex inks partnership with LUNAC Therapeutics to discover novel anticoagulant therapies

              Contact the Supplier

              Lead Product(s): Undisclosed

              Therapeutic Area: Hematology

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: LUNAC Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership February 25, 2020

              Details:

              The partnership aims at discovering a drug that inhibits the protease target, activated Factor XII.

              Fresenius Kabi AG

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Vifor Pharma and Fresenius Kabi create joint venture in China

              Contact the Supplier

              Lead Product(s): Ferric Carboxymaltose

              Therapeutic Area: Hematology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Vifor Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership February 20, 2020

              Details:

              Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China.

              Actinium pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting

              Contact the Supplier

              Lead Product(s): Apamistamab-I-131

              Therapeutic Area: Hematology

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 13, 2020

              Details:

              100% of patients receiving Iomab-B achieving transplant engraftment without delay compared to 18% of patients in the control arm.

              BeyondSpring

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              BeyondSpring’s Plinabulin Activates Adaptive and Innate Immune System

              Contact the Supplier

              Lead Product(s): Plinabulin

              Therapeutic Area: Hematology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 10, 2020

              Details:

              Presentation at the 2020 ASCO-SITC provides strong validation for Plinabulin as a potent activator of the innate immune system.

              Wanbury Limited

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.

              Contact the Supplier

              Lead Product(s): Folic Acid,Iron

              Therapeutic Area: Hematology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cipla

              Deal Size: $12.3 million Upfront Cash: Undisclosed

              Deal Type: Acquisition February 07, 2020

              Details:

              Cipla has acquired the four brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in the women's health segment, Cipla said in a filing to the BSE.

              Achillion

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Alexion Completes Acquisition of Achillion

              Contact the Supplier

              Lead Product(s): Danicopan

              Therapeutic Area: Hematology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

              Deal Size: $930.0 million Upfront Cash: $930.0 million

              Deal Type: Acquisition January 28, 2020

              Details:

              Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases.

              Zydus Cadila

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Zydus inks pact with China Medical System to market Desidustat in Greater China

              Contact the Supplier

              Lead Product(s): Desidustat

              Therapeutic Area: Hematology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: China Medical System Holdings Limited

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 20, 2020

              Details:

              Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.

              Rockwell Medical

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in Ind...

              Contact the Supplier

              Lead Product(s): Triferic

              Therapeutic Area: Hematology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sun Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 14, 2020

              Details:

              Under the terms of the agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic in India and Rockwell Medical will supply the product to Sun Pharma.

              PharmaCompass

              PharmaCompass__DigitalAd